GalMed Medical Research Ltd. researches and develops proprietary drugs for the treatment of lipid metabolism related diseases. The company has developed a series of proprietary fatty acid bile-acid conjugates (FABACs) which selectively inhibit the enzyme Stearoyl-CoA Desaturase (SCD1), a key regulator in lipid metabolism. It's flagship clinical compound Aramchol (arachidyl amido cholanoic acid), has the potential to modify several of the key disorders related to lipid metabolism, including fatty liver, gallstones, diabetes, hyperlipidemia, cancer, and alzheimer's disease. The company is based in Tel Aviv, Israel. GalMed Medical Research Ltd. operates as a subsidiary of Galmed International Ltd.